Captrust Financial Advisors Buys Shares of 11,073 ImmunityBio, Inc. (NASDAQ:IBRX)

Captrust Financial Advisors bought a new stake in ImmunityBio, Inc. (NASDAQ:IBRX) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm bought 11,073 shares of the company’s stock, valued at approximately $41,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. grew its holdings in shares of ImmunityBio by 2.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,265,981 shares of the company’s stock valued at $4,709,000 after purchasing an additional 29,665 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of ImmunityBio by 37.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 621,536 shares of the company’s stock valued at $3,928,000 after acquiring an additional 170,742 shares during the period. Clearwater Capital Advisors LLC lifted its position in shares of ImmunityBio by 8.9% during the 2nd quarter. Clearwater Capital Advisors LLC now owns 482,549 shares of the company’s stock valued at $3,050,000 after acquiring an additional 39,250 shares during the period. Rhumbline Advisers lifted its position in shares of ImmunityBio by 13.3% during the 2nd quarter. Rhumbline Advisers now owns 211,677 shares of the company’s stock valued at $1,338,000 after acquiring an additional 24,802 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of ImmunityBio by 64.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 133,966 shares of the company’s stock valued at $498,000 after acquiring an additional 52,716 shares during the period. 8.58% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on IBRX shares. Piper Sandler reduced their target price on shares of ImmunityBio from $6.00 to $4.75 and set a “neutral” rating for the company in a research note on Monday, August 19th. D. Boral Capital reaffirmed a “buy” rating and set a $30.00 price objective on shares of ImmunityBio in a report on Thursday, November 21st. Finally, EF Hutton Acquisition Co. I raised shares of ImmunityBio to a “strong-buy” rating in a report on Wednesday, October 23rd.

ImmunityBio Trading Up 6.6 %

Shares of ImmunityBio stock opened at $3.06 on Tuesday. ImmunityBio, Inc. has a 12-month low of $2.82 and a 12-month high of $10.53. The company has a market cap of $2.13 billion, a price-to-earnings ratio of -3.33 and a beta of 0.86. The company’s 50-day moving average price is $4.55 and its 200-day moving average price is $4.82.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.